DKSH expands Novartis partnership and DKSH stock costs EUR 74.90

Published on 10/08/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DKSH stock costs EUR 74.90 on October 8, 2026 during the Novartis deal. Net income rose 10.00 percent to CHF 101.1 million in the first half of 2026.

Fotorealistisches Verteilzentrum mit Regalen, Paletten und Gabelstapler in Asien — Fotorealistisches Motiv eines asiatischen Warenlagers passt zu DKSH Holding AG, ISIN CH0012684657, Marktexpansions- und Distributionsdienstleister, Illustration mit AI erstellt.

DKSH stock (ISIN CH0126673539) costs EUR 74.90 at Lang & Schwarz on October 8, 2026 at 12:07 p.m. CEST, as DKSH expands its Singapore healthcare business through a strategic Novartis ophthalmology partnership announced on the same date. According to MarketScreener, the arrangement covers Singapore and includes agency services for Novartis' ophthalmology portfolio.

Novartis adds healthcare scale

DKSH Singapore will provide sales, marketing, credit and collection, and distribution services for the portfolio. The partnership places DKSH's commercial and distribution capabilities alongside Novartis' medicines, giving the Swiss group another concrete healthcare expansion point in a market where access and local execution are central to pharmaceutical commercialization.

The deal is operational rather than financial in its disclosure. The release describes the service scope and patient-access objective, while it does not assign a contract value or earnings contribution. That makes execution, portfolio uptake and regulatory delivery more relevant than a headline revenue estimate.

First-half profit gives the deal context

DKSH's latest reported operating picture was stronger on earnings than on sales. In the first half of 2026, net income rose 10.00 percent to CHF 101.1 million from CHF 91.8 million, while revenue was CHF 5.48 billion versus CHF 5.53 billion in the first half of 2025, according to Simply Wall St.

Adjusted earnings per share increased to CHF 1.67 from CHF 1.41 in the same comparison. The combination of flat revenue and higher net income points to margin and mix as the key financial backdrop for new healthcare mandates such as the Novartis agreement.

Stock stays near its yearly high

On SIX, DKSH was last at CHF 69.90 on October 8, 2026 at 11:48 a.m. CEST. The 52-week range was CHF 52.90 to CHF 70.60 on the same date, putting the SIX quotation CHF 0.70 below its high, while the Lang & Schwarz euro quotation provides the reference price for German investors.

DKSH's market capitalization stood at CHF 4.5 billion on October 8, 2026. The company operates across Healthcare, Consumer Goods, Performance Materials and Technology, so the Novartis agreement strengthens one segment without changing the broader four-part structure.

Trading reference for DKSH investors

DKSH was trading at EUR 74.90 at Lang & Schwarz on October 8, 2026 at 12:07 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of DKSH stock.